About InCephalo
InCephalo is a Healthcare company based in Allschwil (Switzerland) founded in 2021 by Carlo Bertozzi. It operates as a therapeutics for neurological disorders are developed using barrier-retaining technology. Its chief executive is Carlo Bertozzi. InCephalo offers products and services including In C01 and C-Lock Technology. Its focus areas include Life Sciences, Neurology, Drugs and Brain Cancer. Its competitors include Imvax, GT Medical Technologies, Basilea, Laminar Pharma and SOM Biotech and 4 more; 7 of its 9 listed competitors have raised funding.
Company details
InCephalo was founded in 2021 in Allschwil, Switzerland, within the biotechnology sector. Therapeutics targeting neurological disorders are developed, with a focus on proprietary Compartment Lock technology that retains locally applied biologics behind the blood-brain barrier. Operations center on advancing drug candidates for brain-related conditions. The lead product, IL-12, functions as a proinflammatory cytokine to regulate anti-tumor immune responses in brain cancer treatments.
- Headquarters Allschwil, Switzerland
- Founders Carlo Bertozzi
- SectorsHealthcare
- Email••••••••
- Website incephalo.com
- Social LinkedIn
Products & Services of InCephalo
InCephalo offers a comprehensive portfolio of products and services, including In C01 and C-Lock Technology.
Treats brain cancers by enhancing local immune response with reduced toxicity.
Enables localized biologics retention in CNS to minimize systemic side effects.
People of InCephalo
1 people are tracked at InCephalo (1 in leadership).
| Name | Role | Group |
|---|---|---|
Carlo Bertozzi | Co-Founder & CEO | Leadership |
Complete people profiles for InCephalo
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Competitors of InCephalo
InCephalo has 9 listed competitors in our database, 7 of them funded. They include Imvax, GT Medical Technologies, Basilea, Laminar Pharma and SOM Biotech, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| imvax.com | 2015 | Philadelphia, United States | $203.83M | 50 | Patient-specific cell vaccines for glioma treatment are developed. | |
| gtmedtech.com | 2017 | Tempe, United States | $129.94M | 29 | Medical devices for brain tumor radiation therapy are provided. | |
| basilea.com | 1999 | Basel, Switzerland | – | – | Antibiotics, antifungals, and oncology drugs are developed for disease treatment. | |
| laminarpharma.com | 2006 | Palma, Spain | $14.71M | – | Melipathy-based drugs are developed for cancer, Alzheimer's, and inflammation treatments. | |
| sombiotech.com | 2009 | Barcelona, Spain | $28.52M | – | Developer of platform for screening compounds to treat rare diseases | |
| curativebiotech.com | 1995 | Boca Raton, United States | – | – | Therapeutic drugs for cancer, eye, and infectious diseases are developed. | |
| entrinsicbioscience.com | 2012 | Norwood, United States | $19.2M | – | Drugs for tumors, cystic fibrosis, and hemochromatosis are developed. | |
| laevoroc.com | 2019 | Hunenberg, Switzerland | $1.1M | – | Therapeutics for pancreatic, ovarian, breast, and brain cancers are developed. | |
| glionova.com | 2014 | Stockholm, Sweden | $5.7M | – | Develops innovative technologies for novel therapies targeting glioblastoma. |
Detailed competitors of InCephalo
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Neurology
10 companies that operate in the same segment as InCephalo (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | 541 | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about InCephalo
InCephalo was founded in 2021.
InCephalo is headquartered in Allschwil, Switzerland. It is registered at Allschwil, Basel-landschaft, Switzerland.
Carlo Bertozzi is the current CEO of InCephalo. They have also founded this company.
InCephalo was founded in 2021 in Allschwil, Switzerland, within the biotechnology sector. Therapeutics targeting neurological disorders are developed, with a focus on proprietary Compartment Lock technology that retains locally applied biologics behind the blood-brain barrier. Operations center on advancing drug candidates for brain-related conditions. The lead product, IL-12, functions as a proinflammatory cytokine to regulate anti-tumor immune responses in brain cancer treatments.
InCephalo's top competitors include Imvax, GT Medical Technologies and Basilea.
InCephalo offers In C01 and C-Lock Technology.